Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American ...
Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...
The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback